New Drug to Boost Women's Sex Drive Approved in US - NBC 7 San Diego
National & International News
The day’s top national and international news

New Drug to Boost Women's Sex Drive Approved in US

The FDA approved the new drug, Vyleesi, for premenopausal women with a disorder defined by a persistent lack of interest in sex

    processing...

    NEWSLETTERS

    5 Falltacular Ways to Connect With Your Family
    Jacquelyn Martin/AP (File)
    FILE - This Aug. 2, 2018, file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md.

    U.S. women will soon have another drug option designed to boost low sex drive: a shot they can give themselves in the thigh or abdomen that raises sexual interest for several hours.

    The medication OK'd Friday by the Food and Drug Administration is only the second approved to increase sexual desire in a women, a market drugmakers have been trying to cultivate since the blockbuster success of Viagra for men in the late 1990s. The other drug is a daily pill.

    The upside of the new drug "is that you only use it when you need it," said Dr. Julia Johnson, a reproductive specialist at UMass Memorial Medical Center who was not involved in its development. "The downside is that it's a shot — and some people are very squeamish."

    The drug's developer, Amag Pharmaceuticals, could also face some of the same hurdles that have plagued the lone pill previously approved for the condition, including unpleasant side effects and limited insurance coverage.

    Sleeping With the TV on Might Make You Gain Weight

    [NATL] Sleeping With the TV on Might Make You Gain Weight

    In a study published Monday, the National Institutes of Health found that sleeping with a television or light on could lead to weight gain.

    (Published Thursday, June 13, 2019)

    The FDA approved the new drug, Vyleesi, for premenopausal women with a disorder defined by a persistent lack of interest in sex, causing stress. The most common side effect in company studies was nausea. The approval was based on women's responses to questionnaires that showed increases in sexual desire and decreases in stress related to sex. The women didn't report having more sex, the original goal for the drug.

    "Women are not desiring more sex. They want better sex," said Dr. Julie Krop, Amag's chief medical officer.

    Because so many factors affect sexual desire, doctors must rule out other causes before diagnosing the condition, including relationship issues, medical problems and mood disorders. The condition, known as hypoactive sexual desire disorder, is not universally accepted, and some psychologists argue that low sex drive should not be considered a medical problem.

    Still, the pharmaceutical industry has long pointed to surveys — some funded by drugmakers — suggesting that it is the most common female sexual disorder in the nation, affecting roughly 1 in 10 women. Amag estimates nearly 6 million U.S. women meet the criteria for the drug.

    The search for a pill to treat women's sexual difficulties was once a top priority for many of the world's biggest drugmakers, including Pfizer, Bayer and Procter & Gamble. Those companies and others studied and later abandoned drugs acting on blood flow, testosterone and other targets.

    Vyleesi acts on receptors for a brain-stimulating hormone called melanocortin, which is associated with sexual arousal and appetite in both men and women.

    Johnson & Johnson Recalls 33,000 Bottles of Baby Powder

    [NATL] Johnson & Johnson Recalls 33,000 Bottles of Baby Powder

    Johnson & Johnson has voluntarily recalled about 33,000 bottles of Johnson's baby powder after trace amounts of asbestos were discovered. The recall affects one lot shipped in the United States in 2018.

    (Published Friday, Oct. 18, 2019)

    Waltham, Massachusetts-based Amag plans to pitch the drug to consumers through social media, including a website called unblush.com that tells women that low sex drive "is nothing to blush about."

    Amag's campaign has some of the hallmarks that helped launch the first female libido drug, Addyi, a once-a-day pill approved in 2015. The FDA decision followed a contentious four-year review that included a lobbying effort funded by Addyi's maker, Sprout Pharmaceuticals, which framed the lack of female sex drugs as a women's rights issue.

    Women taking Addyi showed a slight uptick in "sexually satisfying events" per month and improved scores on psychiatric questionnaires. Those results were only slightly better than what women taking a placebo reported, but they were significant enough to meet FDA effectiveness standards.

    The pink pill — originally developed as an antidepressant — was ultimately approved with a bold warning that it should not be combined with alcohol, due to risks of fainting and dangerously low blood pressure.

    Most insurers refused to cover the drug, citing lackluster effectiveness, and many women balked at the $800-per-month price. Last year, Sprout slashed the price to $400. It was prescribed just 6,000 times last year, according to investment analyst data.

    UMass's Johnson said drugs should not be the first choice for treating women's sexual problems. Instead, she recommends counseling to help women "separate all the stresses of life" from their sex life.

    Your Dreams of Sleeping in The Goodyear Blimp Can Now Come True

    [NATL] Your Dreams of Sleeping in The Goodyear Blimp Can Now Come True

    Ever dream of spending the night in the Goodyear Blimp? Well, thanks to a partnership between Goodyear and Airbnb your dream can now be reality.

    (Published Wednesday, Oct. 9, 2019)

    "But if that doesn't work, having a medication that may help is worth trying," she said.